Roche Holding - Q1 2026 Earnings Analysis

Performance Highlights

Roche reported Q1 2026 Group sales of CHF 14.7 billion, +6% at constant exchange rates (CER), beating consensus expectations despite a 5% reported CHF decline driven by significant Swiss franc appreciation against the US dollar and other major currencies. Pharmaceuticals grew +7% at CER to CHF 11.5 billion, while Diagnostics grew +3% at CER to CHF 3.3 billion, with both divisions delivering positive underlying momentum.

The top five Pharma growth drivers — Xolair (+26%), Phesgo (+27%), Hemlibra (+13%), Vabysmo (+13%), and Ocrevus (+6%) — generated combined sales of CHF 5.3 billion, up 14% at CER, while Oncology/Hematology grew +3% and Neurology +10%, and Diagnostics' Pathology Lab posted +9% growth with Companion Diagnostics up +23% despite China pricing headwinds dampening Core Lab and Asia-Pacific.

Management Outlook and Forward Catalysts

Management confirmed full-year 2026 guidance for mid single-digit Group sales growth and high single-digit Core EPS growth, both at CER, absorbing an estimated CHF 1 billion loss-of-exclusivity impact and a currency headwind of approximately 11 percentage points on H1 sales. The confirmation signals confidence in the late-stage pipeline's ability to offset legacy biosimilar erosion, with six pivotal Phase III readouts still due in 2026, including divarasib in NSCLC and sefaxersen in IgAN, alongside fenebrutinib's positive RMS data now advancing toward US/EU filing.

Bulls will focus on the breadth of near-term catalysts — Gazyva's SLE PDUFA on 4 December, giredestrant's evERA PDUFA on 18 December, and Phase III obesity data for enicepatide and petrelintide at ADA in June — while bears will watch whether the Diagnostics China recovery materialises in H2 2026, whether currency headwinds persist beyond H1, and whether the imbalance in fatal adverse events observed across fenebrutinib trials poses a regulatory obstacle to what management has positioned as a potential first-in-class franchise in both RMS and PPMS.